User profiles for M. B. Youdim
Moussa YoudimProfessor, Technion-iIsrael Institute of Technology Verified email at technion.ac.il Cited by 76001 |
The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine-opiate system.
MB Youdim, S Yehuda - Cellular and molecular biology (Noisy-le …, 2000 - europepmc.org
Iron is an essential element in maintaining normal structure and functions of the central
nervous system. Dangerous effects of decreases in the bioavailability of iron in the brain are …
nervous system. Dangerous effects of decreases in the bioavailability of iron in the brain are …
PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
Parkinson’s disease affects 5 million people worldwide, but the molecular mechanisms
underlying its pathogenesis are still unclear. Here, we report a genome-wide meta-analysis of …
underlying its pathogenesis are still unclear. Here, we report a genome-wide meta-analysis of …
[HTML][HTML] Selegiline: a molecule with innovative potential
… The first was the elucidation of the novel pharmacological properties of selegiline as a
selective MAO-B inhibitor by Knoll and Magyar and the original idea of Riederer and Youdim, …
selective MAO-B inhibitor by Knoll and Magyar and the original idea of Riederer and Youdim, …
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease
Carbamate derivatives of N-propargylaminoindans (Series I) and N-propargylphenethylamines
(Series II) were synthesized via multistep procedures from the corresponding hydroxy …
(Series II) were synthesized via multistep procedures from the corresponding hydroxy …
[HTML][HTML] Regional siderosis: a new challenge for iron chelation therapy
ZI Cabantchik, A Munnich, MB Youdim… - Frontiers in …, 2013 - frontiersin.org
The traditional role of iron chelation therapy has been to reduce body iron burden via chelation
of excess metal from organs and fluids and its excretion via biliary-fecal and/or urinary …
of excess metal from organs and fluids and its excretion via biliary-fecal and/or urinary …
Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease.
…, L Linert, E Kienzl, E Herlinger, MB Youdim - Journal of neural …, 1995 - europepmc.org
The presence of 5-Hydroxydopamine (5-OHDA) and 6-Hydroxydopamine (6-OHDA) in the
urine of parkinsonian patients on levodopa medication was reported by Andrew et al.(1993). …
urine of parkinsonian patients on levodopa medication was reported by Andrew et al.(1993). …
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.
The discovery that MAO can be differentiated biochemically and pharmacologically into two
forms, types A and B, with different substrate specificities and inhibitor sensitivities has …
forms, types A and B, with different substrate specificities and inhibitor sensitivities has …
Brain iron and dopamine receptor function
MB Youdim, D Ben-Shachar… - Advances in …, 1983 - pubmed.ncbi.nlm.nih.gov
It has been demonstrated that nutritional iron-deficiency induced in rats results in the
reduction of DA D2 receptor binding sites, leading to down-regulation of dopaminergic activity …
reduction of DA D2 receptor binding sites, leading to down-regulation of dopaminergic activity …
The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
MB Youdim, P Riederer - Journal of neural transmission …, 1993 - europepmc.org
In Parkinson's disease (PD) an elevation of iron with staging of the disease has been observed
in the substantia nigra (SN), especially the zona compacta (ZC). The iron is found to be …
in the substantia nigra (SN), especially the zona compacta (ZC). The iron is found to be …
Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases.
S Shoham, MB Youdim - Cellular and Molecular Biology (Noisy-le …, 2000 - europepmc.org
In several neurodegenerative diseases, iron accumulates at sites of brain pathology. Since
post-mortem examination cannot distinguish whether iron accumulation caused the damage …
post-mortem examination cannot distinguish whether iron accumulation caused the damage …